Press Release

 

OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101
News
Press Release
Tue. 22 October 2024

OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101

Read more
OPM announces poster presentation on OPM-101
News
Press Release
Tue. 15 October 2024

OPM announces poster presentation on OPM-101

Read more
OPM announces its first-half 2024 results and provides an update on its clinical developments, and its financial situation
Financial
News
Press Release
Wed. 25 September 2024

OPM announces its first-half 2024 results and provides an update on its clinical developments, and its financial situation

Read more
OPM announces positive results of phase 1 healthy volunteers of OPM-101
News
Press Release
Tue. 16 July 2024

OPM announces positive results of phase 1 healthy volunteers of OPM-101

Read more
Letter to the shareholders n°3
Financial
News
Press Release
Mon. 24 June 2024

Letter to the shareholders n°3

Read more
OPM and Navigo Proteins GmbH sign a strategic collaboration agreement for the research and development of new systemic radiotherapy agents
News
Press Release
Wed. 15 May 2024

OPM and Navigo Proteins GmbH sign a strategic collaboration agreement for the research and development of new systemic radiotherapy agents

Read more
Degroof Petercam initiates coverage of Oncodesign Precision Medicine
Financial
News
Press Release
Thu. 18 April 2024

Degroof Petercam initiates coverage of Oncodesign Precision Medicine

Read more
OPM obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101
Financial
News
Press Release
Wed. 17 April 2024

OPM obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101

Read more
OPM publishes its annual results for 2023 and provides an update on its clinical developments
Financial
News
Press Release
Tue. 26 March 2024

OPM publishes its annual results for 2023 and provides an update on its clinical developments

Read more